biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Midatech at $1.0475

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 31, 2022 3:10pm

72 Views

Post# 35198597

RE:RE:RE:RE:RE:RE:RE:RE:Midatech at $1.0475

If Biodexa and Ladenberg Thalmann did it right the Armistice Capital financing significantly undervalues Biodexa to virtually guarantee that the US$20 million gets on Biodexa's balance sheet. The last thing Biodexa needs is to be caught without cash before it hits key catalysts in this market.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?